Carolina-Studie
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Â
| Official Title: | A Multicentre, International, Randomised, Parallel Group, Double Blind Study to Evaluate Cardiovascular Safety of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. |
The aim of the study is to investigate the longterm impact on cardiovascular morbidity and mortality, relevant efficacy parameters (e.g., glycaemic parameters) and safety (e.g., weight and hypoglycaemia) of treatment with linagliptin in patients with type 2 diabetes at elevated cardiovascular risk receiving usual care, and compare outcome against glimepiride.
Â
| Enrollment: | 6072 |
| Actual Study Start Date: | October 26, 2010 |
| Estimated Study Completion Date: | March 1, 2019 |
| Estimated Primary Completion Date: | February 1, 2019 (Final data collection date for primary outcome measure) |
(https://clinicaltrials.gov/ct2/show/NCT01243424).
Endothelfunktion und Nikotinrezeptorblocker
A phase 2a, randomised, double-blind, placebo-controlled, cross-over, single and multiple dose study to assess the effects of imeglimin on nicotine-induced endothelial dysfunction in young non-smoker healthy male subjects (PXL008-017). Die Studie wird durch das Forschungsinstitut Profil in Mainz. Das isf ist beratend tätig.